Coretox 50 Units: A Professional's Guide to Regulatory & Market Status

Coretox is a botulinum toxin type A product manufactured by Medytox Inc., a prominent biopharmaceutical company based in South Korea. The product is supplied as a lyophilized powder in vials of 50 units, intended for reconstitution before professional use. Medytox is also the manufacturer behind other well-known neurotoxins, positioning Coretox within a portfolio of aesthetic injectables developed for the global market. Unlike some formulations, Coretox is noted for its composition which omits complexing proteins.

Coretox has received approval from the Korean Ministry of Food and Drug Safety (MFDS), formerly known as the KFDA. This certification permits its marketing, distribution, and clinical use within South Korea. The KFDA approval signifies that the product has met the country of origin's rigorous standards for safety, quality, and manufacturing consistency. For international buyers, KFDA approval serves as a foundational indicator of the product's legitimacy and manufacturing oversight.

Beyond market-specific approvals, the manufacturing facilities of Medytox adhere to Good Manufacturing Practice (GMP) standards. GMP certification ensures that products are consistently produced and controlled according to quality standards appropriate to their intended use. This is a critical quality benchmark for any pharmaceutical-grade product. The facilities may also hold ISO certifications, which further attest to the quality management systems in place. These certifications are essential for distributors and clinics that prioritize supply chain integrity when building their botulinum toxin inventory.

The regulatory status of Coretox outside of South Korea varies significantly by region. As of this writing, Coretox does not hold FDA approval for sale in the United States or a CE mark for distribution within the European Union. Its market access in these regions is therefore restricted.

[VERIFY: Specific country registrations in GCC, LATAM, and APAC regions].

In many markets in the GCC, LATAM, and APAC, Coretox is available through licensed importers or parallel import channels, operating under local health authority regulations. It is crucial for buyers in these regions to verify the specific legal and regulatory requirements for importing and using such products in their jurisdiction. This differs from products like Nabota 100unit, another Korean toxin which has secured FDA approval under a different brand name.

For many international clinics, Coretox is sourced via parallel import. This refers to the practice of buying an authentic, approved product from a distributor in one country and importing it for sale into another, outside the manufacturer's formal distribution network. While a common practice in the global aesthetics market, it places a greater responsibility on the buyer to ensure the supplier is reputable and the product is genuine. Sourcing through these channels requires stringent verification of the product's provenance and cold chain management, a topic critical for all injectables as detailed in guides like this one for D.Fill Medium regulatory status.